Growth hor­mone from No­vo Nordisk is in short­age over man­u­fac­tur­ing de­lays

No­vo Nordisk’s growth hor­mone Norditropin is in short­age be­cause of man­u­fac­tur­ing de­lays, ac­cord­ing to an FDA site that tracks drug short­ages as well as the Amer­i­can So­ci­ety of Health-Sys­tem Phar­ma­cists’ short­ages list.

The FDA has short­ages of the drug list­ed for its 5, 10, 15 and 30 mg dos­es, while the phar­ma­cists’ group, al­so known as ASHP, re­port­ed short­ages of the same dos­es, ex­cept for the 15 mg ver­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER